Tech Company Financing Transactions
Tenaya Therapeutics Funding Round
On 3/2/2021, Tenaya Therapeutics raised $106 million in Series C funding from RTW Investments, Casdin Capital and Fidelity Management & Research Company.
Transaction Overview
Company Name
Announced On
3/2/2021
Transaction Type
Venture Equity
Amount
$106,000,000
Round
Series C
Investors
Proceeds Purpose
The new funding will allow Tenaya to advance its lead gene therapy program towards clinical studies; progress new programs towards IND-enabling studies; build on existing drug discovery and development capabilities across its three platforms; and invest in cGMP manufacturing capabilities.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
171 Oyster Point Blvd. 500
San Francisco, CA 94080
USA
San Francisco, CA 94080
USA
Phone
Undisclosed
Website
Email Address
Overview
Tenaya Therapeutics is a biopharmaceutical company with a mission to discover, develop, and deliver potentially curative treatments that target the underlying causes of heart disease. Tenaya is advancing multiple candidates from three product platforms -- Cellular Regeneration, Gene Therapy, and Precision Medicine.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Faraz Ali
Chief Medical Officer
Whit Tingley
Chief Scientific Officer
Timothy Hoey
Vice President
Jay Vora
VP - Manufacturing
Kee-Hong Kim
Browse more venture capital transactions:
Prev: 3/2/2021: Axonius venture capital transaction
Next: 3/2/2021: Artiva Biotherapeutics venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC transactions reported here are sourced from publicly available VC deal announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs